Travere Therapeutics is a biopharmaceutical company dedicated to identifying, developing, and delivering life-changing therapies to people living with rare disease. Although individually uncommon, collectively rare diseases affect a significant number of people—400 million globally, 50% being children. Today, 7,000 rare diseases exist and yet 95% still do not have a single FDA-approved drug treatment. Travere’s 350+ employees who together cultivate a culture of compassion, integrity, and a deep-rooted commitment to people with rare disease are determined to make a difference.
Innovation
Travere is advancing an innovative pipeline of potential first-in-class medicines targeting rare diseases with significant unmet needs and oftentimes no approved medicines. These efforts are led by late-stage development programs of sparsentan, a novel product candidate targeting rare kidney diseases: focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN).
Travere is also advancing pegtibatinase (TVT-058) for the treatment of classical homocystinuria, a genetic metabolic disorder that can cause life-threatening thrombotic events.
The company had three successful topline data readouts for its clinical programs in 2021, and in May 2022, the FDA granted Travere priority review of its New Drug Application for accelerated approval of sparsentan in IgAN. If approved, sparsentan will be the first non-immunosuppressive medicine indicated for IgAN.
Talent Development
Travere’s internal diversity council is charged with creating opportunities for employees to learn from each other’s unique backgrounds and diverse experiences with the goal of using these learnings to better understand the patient communities it serves. The council’s work ranges from learning and development opportunities to ensuring that the company has diverse candidates for new hires.
Travere has introduced programs and initiatives focused on employee well-being. For example, during the pandemic Travere introduced monthly wellness days.
The company also provides caregiver support benefits and a tutoring and back up childcare benefit to support its employees.
Social Responsibility
The company invests in areas beyond the scope of its programs. For example, it sponsors a genetic testing program to help diagnose the cause of newborn cholestasis at no cost to qualifying patients. This program has provided thousands of families with answers and enabled them to seek care typically for conditions outside of Travere’s therapeutic focus.
The company is also working with patient advocates to enhance newborn screening at the state and federal level, championing ways to improve access to care by removing barriers for underserved communities, and promoting access to telehealth, mental and emotional well-being, and new ways to support caregivers and care partners, to name just a few.
Travere is dedicated to improving access to care for traditionally underserved communities, working closely with the Black Women’s Health Imperative (BWHI) to spearhead the formation of the Rare Disease Diversity Coalition (RDDC). Led by BWHI, the coalition exists to address the pressing challenges faced by marginalized populations and identify potential solutions.
